• Smoothened Signaling in Honeybee Olfaction

  2026-09-12

  Guo et al. characterize Apis mellifera Smoothened (Smo) and connect antenna-enriched Hedgehog signaling with olfactory receptor expression, electrophysiological responses, and odor-directed behavior. The study provides a useful insect-model framework for testing Smo function while showing why pharmacological dose, tissue context, and species differences must be considered before translation.

• PRMT5, Splicing, and Glutamine Metabolism in Neuroblastoma

  2026-09-11

  The reference study identifies a linked vulnerability in MYCN-amplified neuroblastoma involving PRMT5-dependent splicing, epitranscriptomic control, and glutamine metabolism. Its combined use of pharmacologic perturbation, RNA sequencing, isotope tracing, m6A analysis, genetic knockdown, and mouse models provides a mechanistic framework for biomarker-led cancer metabolism research.

• circStep Biosensor for Endogenous Protein Dynamics

  2026-09-11

  The reference study introduces circStep, an allosteric genetically encoded RNA biosensor that converts endogenous protein binding into a fluorogenic signal for live-cell localization and abundance tracking. By avoiding direct modification or overexpression of the protein of interest, the platform offers a complementary strategy for studying native protein relocalization and drug-induced transport dynamics.

• 3-hydroxybutyrate (BHBA) in Cell Assays

  2026-09-10

  A scenario-based guide to using 3-hydroxybutyrate (BHBA), SKU M1297, in viability, proliferation, cytotoxicity, and neuroprotection workflows. It addresses dose selection, solvent compatibility, assay interference, mechanistic controls, and evidence-based interpretation with links to product information and the relevant stroke study.

• DiscoveryProbe Protease Inhibitor Library Workflow

  2026-09-10

  Build a defensible protease inhibition workflow around 825 pre-dissolved compounds, from biochemical profiling to cell-based mechanism testing. The approach connects broad protease activity modulation with the PSMD14–CARM1–FERMT1 axis reported in hepatocellular carcinoma research, while emphasizing orthogonal validation and assay troubleshooting.

• Amitriptyline HCl in BBB Assay Design

  2026-09-09

  Amitriptyline HCl can serve as a mechanistically informative probe in blood-brain barrier research. This article translates a validated LLC-PK1-MDR1 permeability model into practical assay decisions that distinguish transport, efflux, and lysosomal trapping.

• CH 223191: Decoding AhR Context in Cell Models

  2026-09-09

  CH 223191 is an aryl hydrocarbon receptor antagonist for separating AhR-dependent signaling from downstream correlation. This article connects dioxin toxicology with microbiota–tryptophan–AhR biology and develops a practical framework for interpreting receptor inhibition in epithelial and environmental models.

• DAPI (hydrochloride) in Host–Pathogen Assays

  2026-09-08

  DAPI (hydrochloride) can serve as a nuclear and DNA-content readout within host–pathogen nanomedicine workflows. This article explains how to use its staining chemistry to separate host-cell injury, cell number, and cell-cycle effects from the antibacterial mechanisms reported for erythrocyte-mimicking nanovesicles.

• Pexmetinib (ARRY-614) Assay Workflow Guide

  2026-09-08

  Build more informative cytokine assays with Pexmetinib (ARRY-614), a dual p38 MAPK and Tie2/Tek inhibitor suited to inflammatory signaling and hematologic research. This workflow connects concentration selection, phospho-signaling measurements, whole-blood testing, and reference-guided troubleshooting without treating pathway suppression as a single endpoint.

• Imipenem Workflows for Antibacterial Research

  2026-09-07

  Imipenem supports controlled studies of bacterial killing, immune response modulation, and localized antimicrobial release. This workflow pairs free-compound assays with a titania nanotube interface inspired by a spatial proteomics study, helping researchers separate antibacterial activity from implant-driven inflammation.

• Machine Learning Designs LNPs for Microglial mRNA

  2026-09-07

  Rafiei, Shojaei, and Chau combined a 216-formulation lipid nanoparticle library with supervised machine learning to identify carriers that deliver mRNA to inflammatory microglia and alter their phenotype. The study selected HA-LNP2 for IL10 mRNA delivery, with evidence of reduced inflammatory signaling in murine and human iPSC-derived microglia.

• Ibuprofen as an Emerging Contaminant: Study Insights

  2026-09-05

  Jan-Roblero and Cruz-Maya’s review integrates ibuprofen pharmacology, environmental occurrence, toxicology, and bacterial biodegradation to explain why a widely used COX inhibitor has become an emerging contaminant. The study’s practical value lies in connecting prostaglandin biology with ecological risk and in identifying biodegradation research as a promising but still incomplete remediation strategy.

• Atrial Natriuretic Peptide: Assay Guide

  2026-09-04

  Learn how rat Atrial Natriuretic Peptide supports better cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide explains handling, assay controls, data interpretation, and vendor selection for SKU A1009.

• Allosteric PDK4 Inhibitors: Evidence from Compound 8c

  2026-09-04

  The reference study describes an anthraquinone-derived series of allosteric pyruvate dehydrogenase kinase 4 inhibitors and identifies compound 8c as a potent lead with an in vitro IC₅₀ of 84 nM. Its metabolic stability, pharmacokinetic behavior, and activity in mouse models of diet-induced obesity, allergic reactions, and cancer support PDK4 as a preclinical target, while also highlighting the limitations of translating these findings to human therapy.

• Telmisartan in Cardiovascular Research

  2026-09-03

  Telmisartan is an angiotensin II receptor antagonist that selectively blocks AT1-receptor signaling and supports hypertension and cardiovascular disease research. Its defined DMSO handling profile and relevance to angiotensin II-driven remodeling make it useful for controlled preclinical experiments, but it should not be misclassified as a direct JAK2/STAT3 or NF-κB inhibitor.

7967 records 6/532 page Previous Next First page 上5页 678910 下5页 Last page